TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11720197
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy alone
Study: 11720197
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy for secondary prevention
Study: 9779765
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil oral suspension (10 mg/kg) administered in fed condition
Study: 9779765
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil oral suspension (10 mg/kg) administered in fasted condition
Study: 2577461
Drug: Benzothiadiazine diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzothiadiazine diuretic agents
Study: 2577461
Drug: Beta-adrenergic receptor-blocking
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic receptor-blocking drugs
Study: 2577461
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both drug classes
Study: 28470550
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution infused at a rate of 125 mL/h
Study: 28470550
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution infused at a rate of 250 mL/h
Study: 28470550
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution boosted with 5% glucose, infused at a rate of 125 mL/h
Study: 24229674
Drug: Enteric-coated lumbrokinase
Normalized name: lumbrokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated lumbrokinase capsules plus standard stroke treatment
Study: 19666939
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of oral calcium supplement, daily, for 8 weeks
Study: 15288159
Drug: Flecainide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (2 mg/kg body weight, maximum 200 mg, given over 20 min)
Study: 15288159
Drug: Ibutilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1 mg or 0.01 mg/kg if less than 60 kg, infused over 10 min)
Study: 15288159
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Flecainide and Ibutilide)
Study: 11288049
Drug: high‐vegetable, fruit,
Approvals — FDA: no, EMA: no, PMDA: no
Description: high‐vegetable, fruit, and nut diet (very‐high‐fiber, 55 g/1,000 kcal)
Study: 8210613
Drug: Nicotine chewing
Normalized name: nicotine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine chewing gum (4 mg)
Study: 3709026
Drug: Nicotine chewing
Normalized name: nicotine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine chewing gum (2 or 4 mg)
Study: 26961367
Drug: Patient-initiated model
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-initiated model of care for botulinum toxin treatment
Study: 26961367
Drug: Standard model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard model of care for botulinum toxin treatment
Study: 22761191
Drug: Sublingual extract
Normalized name: Timothy grass pollen extract Sublingual Tablet [Grastek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual extract of rye grass for 6 months
Study: 20367777
Drug: PDE5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE5 inhibitors plus regular physical activity (≥3 hours/week)
Study: 20367777
Drug: PDE5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE5 inhibitors alone
Study: 20367777
Drug: PDE5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE5 inhibitors plus physical activity
Study: 16043199
Drug: 3 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg.kg(‐1) day(‐1) caffeine intake (G3)
Study: 16043199
Drug: 0 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg.kg(‐1) day(‐1) caffeine intake (G0)
Study: 16043199
Drug: 6 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg.kg(‐1) day(‐1) caffeine intake (G6)
Study: 760698
Drug: Synthetic salmon
Normalized name: Synthetic salmon calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic salmon calcitonin administered subcutaneously
Study: 760698
Drug: Synthetic salmon
Normalized name: Synthetic salmon calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic salmon calcitonin administered in the evening
Study: 25111539
Drug: neostigmine 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: neostigmine 70 μg/kg
Study: 17318498
Drug: Intravenous glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glutamine supplementation (alanyl-glutamine) for 20 hours
Study: 17318498
Drug: Intravenous glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glutamine supplementation (alanyl-glutamine)
Study: 14749232
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 1 x 10(7) CFU/g each of Bifidobacterium lactis and Streptococcus thermophilus
Study: 14749232
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 1 x 10(6) CFU/g each of Bifidobacterium lactis and Streptococcus thermophilus
Study: 9005964
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (PPN) alone (n = 6)
Study: 9005964
Drug: PPN +
Normalized name: Phenylpropanolamine
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PPN + recombinant human growth hormone (rGH) at a daily dose of 0.15 U x kg(‐1) x d(‐1) (n = 6)
Study: 3299095
Drug: Combination amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination amphotericin B and flucytosine for four weeks
Study: 3299095
Drug: Combination amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination amphotericin B and flucytosine for six weeks
Study: 24142329
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (EACA) 150 mg kg(‐1) intravenously prior to incision, followed by 15 mg kg(‐1) h(‐1) infusion until 2 h after graft reperfusion
Study: 23578722
Drug: R-CHOP14 (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP14 (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 40 mg/m² daily for 5 days, administered every 14 days)
Study: 23578722
Drug: R-CHOP21 (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP21 (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 40 mg/m² daily for 5 days, administered every 21 days)
Study: 20053539
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (risperidone, olanzapine, quetiapine IR, ziprasidone, risperidone consta, aripiprazole, paliperidone, quetiapine XR)
Study: 20053539
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment vs Placebo
Study: 17965045
Drug: Repetitive activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive activities of daily living (ADL) activity programme
Study: 16868539
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CT) - cisplatin (50 mg m(‐2)), doxorubicin (45 mg m(‐2)), cyclophosphamide (600 mg m(‐2)) every 28 days for five cycles
Study: 12859554
Drug: Capsaicin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (5 treatments on the first day at 1-hour intervals)
Study: 12859554
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 treatments on the first day)
Study: 8878099
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin with placebo
Study: 8878099
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin with 10 mg flumazenil
Study: 29055953
Drug: Minoxidil 5%
Normalized name: MINOXIDIL 5% SOLN,TOP
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minoxidil 5% solution
Study: 27600184
Drug: Glucose added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose added to fructose in solution
Study: 11916175
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g orally as a single dose)
Study: 19438399
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg orally twice a day for 7 days)
Study: 16705448
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml ICG staining
Study: 16705448
Drug: 1.25 mg/ml
Normalized name: menthol 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/ml ICG staining
Study: 15476576
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg intravenously administered 14 days before bed rest)
Study: 9562008
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 to 8 mg/day)
Study: 9562008
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 to 50 mg/day) plus Amiloride (1.25 to 5 mg/day)
Study: 3107514
Drug: L-deprenyl 10
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-deprenyl 10 mg/d
Study: 3107514
Drug: L-deprenyl 40
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl 40 mg/d
Study: 31389750
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser irradiation (LLLI) applied to one of the two implants (940-nm wavelength, 0.50 ± 2 mW output power, 0.004 cm2 spot size; total delivered energy of 90 J in 3 sessions)
Study: 22030858
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of pivmecillinam treatment
Study: 22030858
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of pivmecillinam treatment
Study: 17042148
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of inhaled budesonide + 5 mg oral montelukast
Study: 17042148
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of inhaled budesonide
Study: 12707491
Drug: Intravenous valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous valproate loading
Study: 12707491
Drug: Oral valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral valproate loading
Study: 10714048
Drug: Ziprasidone (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (5-40 mg/day)
Study: 8262084
Drug: Atenolol and
Normalized name: atenolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol and nifedipine fixed combination
Study: 3085136
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg fluphenazine decanoate
Study: 1860020
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg fluphenazine decanoate
Study: 3085136
Drug: Combined dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dosage groups (5 mg and 25 mg)
Study: 26862696
Drug: Palifermin, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin, 60 mg/kg, intravenously as a single dose 3 days before and after transplant conditioning regimen cycle
Study: 26862696
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo treatment)
Study: 25229957
Drug: Structural Family
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural Family Therapy (SFT)
Study: 8689462
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) - 5 injections at weekly intervals
Study: 8689462
Drug: Intra-articular triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular triamcinolone hexacetonide (TH) - 20 mg followed by 4 placebo (saline) injections
Study: 698165
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg cyanocobalamin injection, three times weekly for 6 weeks
Study: 698165
Drug: Placebo injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection, three times weekly for 6 weeks
Study: 21191143
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g essential amino acids with 10 g l-arginine (ARG)
Study: 15235055
Drug: Intravenous Atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Atrial Natriuretic Peptide (ANP)
Study: 15235055
Drug: Standard conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conventional therapy (Control)
Study: 1964599
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral acyclovir therapy for the suppression of recurrent genital herpes simplex virus infection
Study: 1964599
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral acyclovir therapy
Study: 377878
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin with regular insulin
Study: 377878
Drug: PZI insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PZI insulin with regular insulin
Study: 31860606
Drug: Single-dose stellate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose stellate ganglion block (SGB) with 5 ml of 0.5% ropivacaine
Study: 31860606
Drug: Single-dose stellate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose stellate ganglion block (SGB)
Study: 29670279
Drug: F-652 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-652 (2.0 µg/kg, SC)
Study: 29670279
Drug: F-652 (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-652 (IV infusion at 2.0, 10, 30, and 45 µg/kg)
Study: 29670279
Drug: F-652 (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-652 (IV infusion)
Study: 29670279
Drug: F-652 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-652 (45 µg/kg, IV)
Study: 23684013
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous blood (ABI) alone
Study: 23684013
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous blood (ABI) and intramaxillary fixation (IMF) for 4 weeks
Study: 21063429
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula (SF: 14.1 g/l protein, 662 kcal/l)
Study: 21063429
Drug: Experimental formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formula (EF: 12.8 g/l protein, 662 kcal/l)
Study: 19302900
Drug: Risedronate 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 100 mg/mo
Study: 19302900
Drug: Risedronate 150
Normalized name: risedronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 150 mg/mo
Study: 19302900
Drug: Risedronate 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 200 mg/mo
Study: 19302900
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg/d (active control)
Study: 19302900
Drug: Risedronate 150
Normalized name: risedronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 150 mg/mo and 200 mg/mo
Study: 12911187
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg/d
Study: 10049522
Drug: Interferons (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferons (IFN) beta and gamma in combination with hormonotherapy (Megace or Tamoxifen)
Study: 8281698
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus anticoagulation (aspirin 162.5 mg daily plus heparin followed by aspirin 162.5 mg daily plus warfarin)
Study: 8281698
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (162.5 mg daily)
Study: 8281698
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (aspirin plus anticoagulation)
Study: 30502489
Drug: Vaccine strain
Normalized name: Rubella virus (vaccine strain RA27/3) live antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine strain (mumps vaccine)
Study: 30502489
Drug: Vaccine strain
Normalized name: Rubella virus (vaccine strain RA27/3) live antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine strain vs Wild-type virus
Study: 27402475
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (250,000 IU, one-time oral dose)
Study: 25967093
Drug: Intensified work-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified work-related rehabilitation aftercare program (including functional capacity training, psychosocial groups, social counseling, relaxation training, and exercise therapy)
Study: 25967093
Drug: Standard intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intensified rehabilitation aftercare (consisting of only exercise therapy)
Study: 25549015
Drug: Ginger (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (as a drug)
Study: 15202299
Drug: Cytotoxic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic and glucocorticoid therapy
Study: 15202299
Drug: Before therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before therapy
Study: 8106625
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (200 mg/day)
Study: 8302150
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg epidural morphine in 10 mL normal saline with epinephrine 0.1 mg (1:100,000, 10 micrograms/mL)
Study: 8302150
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg epidural morphine in 10 mL normal saline without epinephrine
Study: 3731824
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg sustained-release oxprenolol once daily
Study: 3731824
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide/50 mg triamterene once daily
Study: 3731824
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 160 mg sustained-release oxprenolol and 25 mg hydrochlorothiazide/50 mg triamterene once daily
Study: 3731824
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg sustained-release oxprenolol alone
Study: 3731824
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide/50 mg triamterene alone
Study: 2534412
Drug: Hydrochlorothiazide treatment
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide treatment
Study: 28815997
Drug: Twice-daily sustained-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily sustained-release (SR) paracetamol (2 × 1000 mg twice daily)
Study: 22811926
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (1 capsule/day) for 6 months after a wash-out period
Study: 22811926
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (1 capsule/day)
Study: 18489612
Drug: Darifenacin 15
Normalized name: darifenacin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 15 mg for 1 week
Study: 18489612
Drug: Atropine (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (nonselective muscarinic antagonist)
Study: 2386447
Drug: scopolamine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine (1.0 mg)
Study: 7389389
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg 3-times daily
Study: 7389389
Drug: Amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 250 mg 3-times daily
Study: 31775843
Drug: SHGBZK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHGBZK treatment
Study: 24599676
Drug: Balneotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy plus physical therapy (n=37)
Study: 24599676
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy alone (n=44)